z-logo
Premium
Progression and survival in P arkinson's disease with subthalamic nucleus stimulation
Author(s) -
Lilleeng B.,
Brønnick K.,
Toft M.,
Dietrichs E.,
Larsen J. P.
Publication year - 2014
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/ane.12224
Subject(s) - subthalamic nucleus , parkinson's disease , deep brain stimulation , neuroscience , stimulation , degenerative disease , medicine , central nervous system disease , psychology , physical medicine and rehabilitation , disease
Background Treatment for P arkinson's disease (PD) is symptomatic. Surgical treatment with continuous high‐frequency stimulation of the subthalamic nucleus ( STN ‐ DBS ) is established as a safe symptomatic treatment with long‐term beneficial effects. It has been postulated that STN ‐ DBS could halt the progression of PD through a disease modifying or neuroprotective effect. Objective To investigate the postulated disease modifying or neuroprotective effect of STN ‐ DBS by comparing the rate of deterioration of parkinsonism and mortality over time in two selected and matched groups of patients with PD with and without surgery. Methods Group A was derived from all patients who received STN ‐ DSB surgery at O slo U niversity H ospital, from J anuary 2001 to D ecember 2007. Group B was derived from a prevalence study of PD in the S tavanger area of W estern N orway in 1993. The two groups were individually matched and the disease progression measured by U nified P arkinson's D isease R ating S cale‐motor scores, and the mortality was compared. Results The mean annual change based on baseline and last observation scores in individually matched groups was 0.97 ( SD  = 3.57) for the surgery group and 1.04 ( SD  = 3.33) for the controls and thus not significantly different, F (1, 104) = .21, P  = 0.89. The long‐term mortality was also similar in the two groups during long‐term follow‐up, hazard ratio = 1.76, CL 0.91–3.40, P  = 0.091. Conclusion This study gives no support to a postulated disease modifying or neuroprotective effect of STN ‐ DBS in patients with PD .

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom